Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

GIP (native; Isoglycaemic Clamp Infusion)

MARKETED

GIP (native infusion)

2
graded findings
2
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 1Very low evidence 0

GIP (native; Isoglycaemic Clamp Infusion) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GIP (native; Isoglycaemic Clamp Infusion) MARKETED
heart-rate-chronotropy No change
Low evidence

Under a two-stage somatostatin (pancreatic) clamp in healthy young men (n=10), native GIP infusion produced NO change in heart rate, blood pressure or flow-mediated...

Karstoft K et al., Am J Physiol Endocrinol Metab 2015;308(5):E426-33 Source
Full findingUnder a two-stage somatostatin (pancreatic) clamp in healthy young men (n=10), native GIP infusion produced NO change in heart rate, blood pressure or flow-mediated dilation; the sole haemodynamic change was increased femoral-artery blood flow during hyperglycaemia. The cleanest isolating human GIP haemodynamic dataset - a measured HR null under acute infusion.
Populationhealthy young men, n=10, two-stage pancreatic (somatostatin) clamp, GIP infusion 1.5 pmol/kg/min
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitssmall sample (N~10); surrogate/exploratory endpoint
Comparatorscontrol; GLP-1
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GIP (native; Isoglycaemic Clamp Infusion) MARKETED
Appetite and food intake No change
Moderate evidence

In a randomised crossover isoglycaemic-clamp study in 17 overweight/obese men, GIP infusion ALONE did not reduce ad libitum energy intake vs saline, whereas GLP-1...

Bergmann NC et al., Diabetologia 2019;62(4):665-675 Source
Full findingIn a randomised crossover isoglycaemic-clamp study in 17 overweight/obese men, GIP infusion ALONE did not reduce ad libitum energy intake vs saline, whereas GLP-1 alone did; adding GIP did not potentiate GLP-1, and intake on GIP+GLP-1 was significantly HIGHER than on GLP-1 alone — acute human GIP attenuated rather than aided GLP-1's intake suppression.
PopulationOverweight/obese men, n=17, crossover (NCT02598791)
Fundingacademic - Innovation Fund Denmark and the Vissing Foundation
Scope limitssmall sample (N~17)
Comparatorssaline; GLP-1; GIP+GLP-1